Aria CV is a technology company.
Aria CV has raised $39.0M across 2 funding rounds.
Aria CV has raised $39.0M in total across 2 funding rounds.
Aria CV is a medical technology company developing an implantable device to treat pulmonary hypertension (PH), specifically Pulmonary Arterial Hypertension (PAH), a progressive disease affecting over 70 million people worldwide.[1][2][4] The device reduces right ventricle afterload and increases cardiac output by restoring blood flow, using only the heart's motion without batteries, pumps, or electronics; it consists of a reservoir, balloon, narrow conduit, and nitinol anchor.[1][2][3][4] Founded in 2010 and based in Plymouth, Minnesota, Aria CV has raised $50.71M total, including a $31M Series B led by Xeraya Capital, and remains in Series B-III stage with recent funding 8 months ago.[1][3] It serves patients with PAH via healthcare professionals in clinical investigations, addressing unmet needs in drug-limited treatments with potentially fewer side effects.[2]
Aria CV was founded in 2010 by Drs. John Scandurra and Karl Vollmers, Fellows at the University of Minnesota, who studied medical literature, developed prototypes, tested them in animals, and licensed a patent from the university to create the company.[2][5] The idea emerged from recognizing PAH's large unmet needs despite drug therapies, leading to a novel device-based approach that leverages heart motion for relief.[2] Dan Gladney became CEO in April 2019, bringing 22 years of medical device leadership, including roles at ReShape Lifesciences, Lanx (acquired by Biomet), Heart Leaflet Technologies (acquired by Bracco for $84M), ACIST Medical Systems, and Compex Technologies.[5] Early traction included animal testing and patent filing, evolving into significant Series B funding.[1][3]
Aria CV rides the trend of innovative cardiovascular devices amid rising demand for PH/PAH solutions, where drugs fall short for 70 million affected globally.[2][4] Timing aligns with advances in nitinol anchors and heart-motion tech, plus investor interest shown in $50M+ funding from Xeraya, Longview Ventures, and others.[1][3] Market forces favor it: aging populations, PH prevalence, and shifts to device-based therapies over pharmaceuticals with side effects.[2] It influences the ecosystem by pioneering non-powered implants, potentially accelerating PAH research and attracting strategic healthcare investors.[1][3]
Aria CV's investigational device positions it for pivotal clinical trials and potential FDA pathways, building on Series B momentum and leadership exits.[1][3][5] Trends like AI-integrated cardio monitoring (e.g., peers like AliveCor) and remote health will amplify demand, but regulatory hurdles and competition in PH devices loom.[1] Its influence may grow via partnerships or acquisition by majors like Biomet/Bracco alumni networks, evolving from startup to PAH therapy leader if trials succeed—echoing its origin as a university patent turned funding magnet.[2][5]
Aria CV has raised $39.0M in total across 2 funding rounds.
Aria CV's investors include BioStar Ventures, Broadview Ventures.
Aria CV has raised $39.0M across 2 funding rounds. Most recently, it raised $31.0M Series B in February 2020.
| Date | Round | Lead Investors | Other Investors |
|---|---|---|---|
| Feb 1, 2020 | $31.0M Series B | BioStar Ventures, Broadview Ventures | |
| Jul 1, 2015 | $8.0M Series A | BioStar Ventures, Broadview Ventures |